<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03072485</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-37203</org_study_id>
    <nct_id>NCT03072485</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers</brief_title>
  <official_title>Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anne Chang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study in healthy adult volunteers to examine the effects of 3 FDA approved
      medications on skin aging when applied in topical form. This is an open label, placebo
      controlled study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint of the study is the profile of differences in transcript levels of
      age-associated genes such as those in the lamin-A, insulin like growth factor (IGF) and NFKB
      pathways as well as noncoding RNAs in topical agent-exposed arm skin versus placebo exposed
      arm skin in healthy volunteers. The secondary endpoints include (1) differences in skin
      wrinkling using a 4 point Likert scale for wrinkle severity between placebo and topical agent
      exposed arm skin after 4 weeks of usage; (2) the type and severity of adverse events, both
      systemic and skin localized after exposure to both topical agent and placebo vehicle cream.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Profile of gene transcript changes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Profile of gene transcript changes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wrinkle score</measure>
    <time_frame>4 weeks</time_frame>
    <description>on Likert scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Aging</condition>
  <arm_group>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>First five enrolled participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin, diclofenac</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sixth to tenth enrolled participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Topical sirolimus applied to the skin</description>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Topical metformin applied to the skin</description>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
    <arm_group_label>Metformin, diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <description>Topical diclofenac applied to the skin</description>
    <arm_group_label>Sirolimus, metformin, diclofenac</arm_group_label>
    <arm_group_label>Metformin, diclofenac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 55 years

          2. Female

          3. All 4 grandparents of European descent

          4. Fitzpatrick Skin type 1-3 (fair skin type)

          5. Presence of moderate to severe fine wrinkling on arm skin

          6. Presence of moderate to severe dyspigmentation on arm skin

          7. Normal or overweight body mass index

        Exclusion Criteria:

          1. History of laser treatment or chemical peels to to arm

          2. History of topical anti-aging products (includes retinol, tretinoin, tazarotene,
             azelaic acid, hydroquinone) to skin within 6 weeks of starting study

          3. History of surgical procedures to arm skin area including removal of benign or
             malignant skin cancers in the area of topical study agent application

          4. Current skin conditions in the area of arms including seborrheic keratosis, rosacea,
             eczema that may obscure study assessment

          5. History of abnormal scarring

          6. Uncontrolled medical problems including concurrent infection or malignancy at time of
             enrollment

          7. Unable to provide and sign written informed consent

          8. Unable to comply with study-related procedures including keeping study diary,
             application of topical study agents, avoidance of direct sun exposure &gt;5 minutes per
             day or ultraviolet tanning bed usage

          9. Not willing to provide two small skin biopsies at end of study

         10. Known allergy to sirolimus, diclofenac or metformin.

         11. Known immunosuppression including organ transplant, HIV, autoimmune disease, and
             chronic leukemia or lymphoma

         12. Fasting blood sugar above the upper limit of normal for Stanford laboratory

         13. Diarrhea

         14. Use of greater than one alcoholic beverage per day

         15. Stress such as surgery or trauma within 2 weeks of enrollment

         16. Liver disease such as hepatitis B or C

         17. Planning to embark on dieting, caloric restriction or new exercise regimen during the
             study to lose weight.

         18. Unable to refrain from using any topical agent on arms besides the study agents
             provided for duration of study.

         19. Hematocrit, hemoglobin, platelets, white blood cell count, serum Na, K, Cr, aspartate
             aminotransferase (AST), alanine aminotransferase (ALT) greater or lesser than 1.5
             times limits of normal.

         20. History of heart failure, coronary artery disease, including angina, coronary artery
             bypass graft, pacemaker or stent placement

         21. History of bleeding or ulcers of the gastrointestinal tract

         22. History of diabetes mellitus

         23. Current use of blood thinners (includes heparin, warfarin and aspirin)

         24. Current use of strong cytochrome P 450 (CYP) 3A4 inhibitor and/or P-gp (examples
             include ketoconazole, voriconazole, itraconazole, erythromycin, clarithromycin) or
             strong inducers of CYP3A4 and/or P-gp (examples include rifampin or rifabutin)

         25. Abnormal lipid panel as defined by upper limit of normal at Stanford laboratory
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Chang, MD</last_name>
    <phone>650 721 7151</phone>
    <email>alschang@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michaella Montana, BS</last_name>
    <phone>650 721 7195</phone>
    <email>mmontana@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Dermatology</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Chang, MD</last_name>
      <phone>650-721-7151</phone>
      <email>alschang@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michaella Montana, BS</last_name>
      <phone>650 721 7159</phone>
      <email>mmontana@stanford.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Anne Chang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>aging</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

